Aardvark Therapeutics(AARD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AARD Aardvark Therapeutics

Post-Mkt 08-25 19:29:20 EDT

7.25

+0.37

+5.38%

盘后7.39

+0.14+1.89%

19:22 EDT

High7.31	Low6.49	Vol145.10K
Open6.94	D1 Closing6.88	Amplitude11.92%
Mkt Cap157.30M	Tradable Cap80.97M	Total Shares21.70M
T/O1.02M	T/O Rate1.30%	Tradable Shares11.17M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"AARD","market":"US","secType":"STK","nameCN":"Aardvark Therapeutics","latestPrice":7.25,"timestamp":1787688000000,"preClose":6.88,"halted":0,"volume":145101,"hourTrading":{"tag":"盘后","latestPrice":7.3869,"preClose":7.25,"latestTime":"19:22 EDT","volume":5552,"amount":41178.0974736,"timestamp":1787700123179,"change":0.1369,"changeRate":0.018883,"amplitude":0.065214},"delay":0,"changeRate":0.05377906976744188,"floatShares":11168300,"shares":21696893,"eps":-3.207951,"marketStatus":"Post-Mkt","change":0.37,"latestTime":"08-25 19:29:20 EDT","open":6.94,"high":7.31,"low":6.49,"amount":1015304.3447250001,"amplitude":0.119186,"askPrice":7.4,"askSize":400,"bidPrice":6.69,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-3.207951,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787702400000},"marketStatusCode":4,"adr":0,"listingDate":1739509200000,"exchange":"NASDAQ","adjPreClose":6.88,"preHourTrading":{"tag":"盘前","latestPrice":6.8,"preClose":6.88,"latestTime":"09:29 EDT","volume":145,"amount":956.699908,"timestamp":1787664580039,"change":-0.08,"changeRate":-0.011628,"amplitude":0.098837},"postHourTrading":{"tag":"盘后","latestPrice":7.3869,"preClose":7.25,"latestTime":"19:22 EDT","volume":5552,"amount":41178.0974736,"timestamp":1787700123179,"change":0.1369,"changeRate":0.018883,"amplitude":0.065214},"volumeRatio":0.943549,"impliedVol":3.3083,"impliedVolPercentile":0.953},"requestUrl":"/m/hq/s/AARD/wiki","defaultTab":"wiki","newsList":[{"id":"2661329772","title":"Aardvark Therapeutics Lawsuit Alleges Investors Were Misled Before Sharp AARD Stock Drops","url":"https://stock-news.laohu8.com/highlight/detail?id=2661329772","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661329772?lang=en_us&edition=fundamental","pubTime":"2026-08-21 04:18","pubTimestamp":1787257097,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics, Inc. (NASDAQ: AARD) is facing a federal securities lawsuit alleging that investors were misled about the safety profile, reg...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/class-action/aardvark-therapeutics-lawsuit-alleges-investors-were-misled-before-sharp-aard-stock-drops?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/class-action/aardvark-therapeutics-lawsuit-alleges-investors-were-misled-before-sharp-aard-stock-drops?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ISBC","PSQ","QDTE","AARD","QLD","TECS","SQQQ","TQQY","TQQQ","QQQE","QQQY","QID","QQQA","NVIW.SI","NQmain","QQQ","GPIQ","MNQmain","FTEC","BK4007","JEPQ","NDX","ONEQ","BK4211","QQQJ","QYLG","QQQM","IYW",".IXIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660087432","title":"Aardvark Therapeutics Shareholders Approve Governance and Incentives","url":"https://stock-news.laohu8.com/highlight/detail?id=2660087432","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660087432?lang=en_us&edition=fundamental","pubTime":"2026-08-18 04:56","pubTimestamp":1787000185,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Aardvark Therapeutics, Inc. ( ($AARD) ). At its August 14, 2026 annual meeting, Aardvark Therapeutics, Inc. rec...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aardvark-therapeutics-shareholders-approve-governance-and-incentives?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aardvark-therapeutics-shareholders-approve-governance-and-incentives?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660434014","title":"Aardvark Therapeutics Held Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2660434014","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660434014?lang=en_us&edition=fundamental","pubTime":"2026-08-18 04:11","pubTimestamp":1786997466,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics held annual shareholder meetingAardvark Therapeutics held its 2026 annual shareholder meeting on Aug. 14, 2026.Shareholders ratified BDO USA as independent auditor for the year e","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDLPz3gH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659123665","title":"Analysts Offer Insights on NA Companies: Nakamoto Inc (NAKA) and Aardvark Therapeutics, Inc. (AARD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659123665","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659123665?lang=en_us&edition=fundamental","pubTime":"2026-08-15 00:40","pubTimestamp":1786725608,"startTime":"0","endTime":"0","summary":"Companies in the NA sector have received a lot of coverage today as analysts weigh in on Nakamoto Inc (NAKA) and Aardvark Therapeutics, Inc. (AARD)...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-nakamoto-inc-naka-and-aardvark-therapeutics-inc-aard-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-nakamoto-inc-naka-and-aardvark-therapeutics-inc-aard-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4141","NAKA","BK4007","AARD","NA","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659508152","title":"PDS Biotechnology Q2 Net Loss Widens Slightly as Operating Costs Fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2659508152","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659508152?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:39","pubTimestamp":1786624789,"startTime":"0","endTime":"0","summary":"PDS Biotechnology Q2 net loss widens slightly as operating costs fallOverviewUS cancer immunotherapy developer's Q2 net loss widened slightly yr/yrOperating expenses fell due to lower clinical trial a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A0LJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMNM","PDSB","AARD","CRDF","BK4007","BK4139","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659154351","title":"Grace Therapeutics Q1 Net Loss Widens on Impairment Charges","url":"https://stock-news.laohu8.com/highlight/detail?id=2659154351","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659154351?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:08","pubTimestamp":1786622937,"startTime":"0","endTime":"0","summary":"Grace Therapeutics Q1 net loss widens on impairment chargesOverviewUS biopharma firm's Q1 net loss widened on impairment charges tied to deprioritized programsResearch and admin expenses fell as GTx-1","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A0JR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRX","AARD","GRCE","BK4007","ELOX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659151345","title":"Stifel Nicolaus Keeps Their Hold Rating on Aardvark Therapeutics, Inc. (AARD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659151345","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659151345?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:35","pubTimestamp":1786620948,"startTime":"0","endTime":"0","summary":"In a report released today, James Condulis from Stifel Nicolaus reiterated a Hold rating on Aardvark Therapeutics, Inc., with a price target of $6....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-keeps-their-hold-rating-on-aardvark-therapeutics-inc-aard-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-keeps-their-hold-rating-on-aardvark-therapeutics-inc-aard-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SF","AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659567411","title":"Indaptus Q2 Net Loss Narrows as Costs Fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2659567411","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659567411?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:16","pubTimestamp":1786619798,"startTime":"0","endTime":"0","summary":"Indaptus Q2 net loss narrows as costs fallOverviewU.S. immunotherapy biotech's Q2 net loss narrowed, driven by lower clinical and payroll costsCompany discontinued Decoy20 clinical study and has no ac","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A0GZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRX","BK4007","INDP","BK4139","AARD","TXMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659135164","title":"AI Risk and Regulation: How Aardvark Therapeutics’ Use of Artificial Intelligence Could Expose It to Compliance, Cybersecurity, and Competitiveness Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2659135164","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659135164?lang=en_us&edition=fundamental","pubTime":"2026-08-13 14:00","pubTimestamp":1786600830,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics, Inc. (AARD) has disclosed a new risk, in the Technology category. Aardvark Therapeutics, Inc. faces material risk from its p...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ai-risk-and-regulation-how-aardvark-therapeutics-use-of-artificial-intelligence-could-expose-it-to-compliance-cybersecurity-and-competitiveness-challenges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ai-risk-and-regulation-how-aardvark-therapeutics-use-of-artificial-intelligence-could-expose-it-to-compliance-cybersecurity-and-competitiveness-challenges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AIPO","BK4007","BK4585","AARD","VTHR","BK4588","NTSK","QTOC","BUG","AGIX","HACK","ARTY","BK4097","IHAK","CHAT","CIBR","TEKX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659900653","title":"Atara Biotherapeutics Q2 Revenue Falls on Deferred Revenue Recognition","url":"https://stock-news.laohu8.com/highlight/detail?id=2659900653","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659900653?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:14","pubTimestamp":1786565663,"startTime":"0","endTime":"0","summary":"Atara Biotherapeutics Q2 revenue falls on deferred revenue recognitionOverviewUS T-cell immunotherapy developer's Q2 revenue beat analyst expectations, but fell sharply yr/yrCompany reported Q2 net lo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL1N449110:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PROK","AARD","PLRX","ATRA","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658905961","title":"Aardvark Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2658905961","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658905961?lang=en_us&edition=fundamental","pubTime":"2026-08-12 22:41","pubTimestamp":1786545706,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings SummaryAardvark Therapeutics, Inc.AARD.OQreported a quarterly adjusted loss of 66 cents per share for the quarter e","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL8N4491LH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658971236","title":"Cypherpunk Technologies Swings to Q2 Profit on Zcash Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=2658971236","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658971236?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:14","pubTimestamp":1786533258,"startTime":"0","endTime":"0","summary":"Cypherpunk Technologies swings to Q2 profit on Zcash gainsOverviewUS privacy tech firm's Q2 net income turned positive, driven by unrealized gains on Zcash holdingsQ2 diluted EPS was $0.18, reversing ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL1N4490DV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CYPH","BK4139","AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658758689","title":"Analysts Offer Insights on NA Companies: Smithfield Foods (SFD), Douglas AG (OtherDOUDF) and Aardvark Therapeutics, Inc. (AARD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658758689","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658758689?lang=en_us&edition=fundamental","pubTime":"2026-08-12 17:20","pubTimestamp":1786526421,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the NA sector with new ratings on Smithfield Foods (SFD), Douglas AG (DOUDF) and Aardvark Therapeutics, Inc...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-smithfield-foods-sfd-douglas-ag-otherdoudf-and-aardvark-therapeutics-inc-aard-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-smithfield-foods-sfd-douglas-ag-otherdoudf-and-aardvark-therapeutics-inc-aard-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AARD","BK4141","BK4200","BK4212","SILJ","BK4007","SFD","BK4210","SLVR","SLJY","DOUDF","SLVX","NA","FXG","AG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658945726","title":"Aardvark Therapeutics Q2 Operating Expenses Fall on Paused ARD-101 Clinical Trials and Workforce Reduction","url":"https://stock-news.laohu8.com/highlight/detail?id=2658945726","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658945726?lang=en_us&edition=fundamental","pubTime":"2026-08-12 05:04","pubTimestamp":1786482254,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics Q2 operating expenses fall on paused ARD-101 clinical trials and workforce reductionOverviewUS biopharma firm's Q2 net loss narrowed and beat analyst expectationsOperating expens","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL1N44812F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRX","BOLT","BK4007","BK4139","AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658945165","title":"Aardvark Therapeutics Inc Q2 Net Income USD -14.387 Million VS. Ibes Estimate USD -20.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658945165","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658945165?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:53","pubTimestamp":1786481615,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nPLXG3XWTT:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658945143","title":"Aardvark Therapeutics Q2 EPS $-0.66","url":"https://stock-news.laohu8.com/highlight/detail?id=2658945143","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658945143?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:53","pubTimestamp":1786481615,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nPLXG3XWTT:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658894516","title":"Aardvark Therapeutics Inc Q2 Operating Expenses USD 15.084 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658894516","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658894516?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:53","pubTimestamp":1786481615,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nPLXG3XWTT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658451669","title":"Aardvark Therapeutics Inc Q2 Income from Operations USD -15.084 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658451669","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658451669?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:53","pubTimestamp":1786481615,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nPLXG3XWTT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658451129","title":"Press Release: Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2658451129","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658451129?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:53","pubTimestamp":1786481580,"startTime":"0","endTime":"0","summary":"and the OLE  trial to assess the totality of. available efficacy and safety data and to support an informed. determination of next steps for the ARD-101 program. In June 2026, the. Company terminated the HERO and the OLE trial and does not currently. intend to resume these trials as previously designed.-- In May 2026, the Company announced that the U.S. Food and Drug. Administration  placed a full clinical hold on its investigational. new drug application  for ARD-101, related to the Company's. previously announced voluntary pause. The clinical hold applies to all. previously ongoing clinical studies under the IND, including the Phase 3. HERO trial evaluating ARD-101 for the treatment of hyperphagia in. patients with Prader-Willi Syndrome  and the Phase 3 OLE trial.Second Quarter 2026 Financial Highlights-- Cash Position: As of June 30, 2026, Aardvark had cash, cash equivalents. and short-term investments of $73.9 million, compared to $91.2 million as. of March 31, 2026. Based on curre","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDNA","MEDX","NVIB","IND","HYLG","GDOC","AARD","BK4007","BMED","PWS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657641628","title":"Aardvark Therapeutics, Inc. Expected to Post a Loss of 87 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2657641628","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657641628?lang=en_us&edition=fundamental","pubTime":"2026-08-07 21:55","pubTimestamp":1786110905,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics, Inc. <AARD.OQ> expected to post a loss of87cents a share - Earnings PreviewAardvark Therapeutics, Inc.AARD.OQAARD.Ois expected to  show no change in quarterly revenue when it re","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL8N4441IR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://aardvarktherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0208},{"period":"1month","weight":0.0886},{"period":"3month","weight":0.6381},{"period":"6month","weight":-0.4443},{"period":"1year","weight":-0.2958},{"period":"ytd","weight":-0.4758}],"compareEarnings":[{"period":"1week","weight":-0.0119},{"period":"1month","weight":0.0332},{"period":"3month","weight":0.0172},{"period":"6month","weight":0.1014},{"period":"1year","weight":0.1831},{"period":"ytd","weight":0.1196}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"exchange":"NASDAQ","name":"Aardvark Therapeutics","nameEN":"Aardvark Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aardvark Therapeutics(AARD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Aardvark Therapeutics(AARD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Aardvark Therapeutics,AARD,Aardvark Therapeutics股票,Aardvark Therapeutics股票老虎,Aardvark Therapeutics股票老虎国际,Aardvark Therapeutics行情,Aardvark Therapeutics股票行情,Aardvark Therapeutics股价,Aardvark Therapeutics股市,Aardvark Therapeutics股票价格,Aardvark Therapeutics股票交易,Aardvark Therapeutics股票购买,Aardvark Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aardvark Therapeutics(AARD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Aardvark Therapeutics(AARD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}